Insulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations.
The company, however, yesterday evening raised the low end of its revenue guidance range to 16–20%. The range was previously 15–20%.
The Acton, Mass.-based company a net loss of $0.0 million, or 0¢ per diluted share, on sales of $246.1 million for the three months ended March 31 — versus a net loss of –$2.1 million, or –3¢ per share for Q1 2020. Sales were up 27.4%.
Adjusted to exclude one-time items, earnings per share were $0.00. Analysts were looking for EPS of 8¢ on sales of $247.1 million.
Get the full story from our sister site, Drug Delivery Business.
This story originally ran Thursday, May 6, 2021. Updated May 7 to include day-after stock price.